No Detail Found!

A comparison between liposomal and nonliposomal formulations of doxorubicin in the treatment of cancer: An updated review

Author(s)
Yik Hoe Ngan School of Pharmacy, Monash University Malaysia,Jalan Lagoon Selatan, 47500 Bandar Sunway, Selangor,Malaysia
Manish Gupta School of Pharmacy, Monash University Malaysia,Jalan Lagoon Selatan, 47500 Bandar Sunway, Selangor,Malaysia
Abstract
Cancer remains a major cause of hospitalization and death every year. From time to time, new formulations of anticancer drugs are available in the market and draw the concern of healthcare professionals in terms of the superiority, toxicology, and cost-effectiveness of the new formulations in comparison to the conventional formulation of the same drugs. Doxorubicin, which is a highly potent chemotherapeutic agent, comes with three formulations (pegylated liposomal, nonpegylated liposomal and nonliposomal conventional formulations). Englishl-anguage literature in relation to the three formulations has been reviewed to inform the healthcare professionals regarding the differences between these formulations. In terms of efficacy, there is only one study supporting the superiority of liposomal doxorubicin, but there are more data which supports the non- inferiority of liposomal doxorubicin in comparison to conventional non- liposomal doxorubicin. It is emphasized that liposomal doxorubicin promotes better toxicology profile than nonliposomal conventional doxorubicin with an increased cost. The cost-effectiveness of liposomal doxorubicin is not well defined as there are very limited studies in this area. Apart from that, this review highlights the interpatient variability in regards to the clearance and volume of distribution following the administration of liposomal doxorubicin. In conclusion, further studies will be required to better define the superiority of liposomal formulation of doxorubicin regarding the efficacy and dose standardization of liposomal doxorubicin should be sought in the near future.
Publication Details
Page(s) 1-13
DOI DOI not available
Published Journal: Archives of Pharmacy Practice, Volume: 7, Issue: 1, Year: 2016

Request the full text from PASTIC

Keywords
Doxorubicin, liposome, Cancer
References
Cancer National .2015 .Institute. Last updated on 2015 Mar 02; Last cited on 2015 Oct, 15 : .
Aulton M,Taylor K M .2013 .Aulton's Pharmaceutics: The Design and Manufacture of Medicines. , : 790-5.
Rang HP,Maureen DM .2012 .Rang & Dale's Pharmacology. , : 673-88.
Allen TM,Cullis PR .2013 .Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev, 65 : 36-48.
Duggan ST,Keating GM .2011 .Pegylated liposomal doxorubicin: A review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS‑related Kaposi's sarcoma. Drugs, 71 : 2531-58.
Berger JL,Smith A,Zorn KK,Sukumvanich P,Olawaiye AB,Kelley J .2014 .Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era. Onco Targets Ther, 7 : 1409-13.
Wasle I,Gamerith G,Kocher F,Mondello P,Jaeger T,Walder A .2015 .Nonp‑egylated liposomal doxorubicin in lymphoma: Patterns of toxicity and outcome in a large observational trial. Ann Hematol, 94 : 593-601.
La‑Beck NM,Zamboni BA,Gabizon A,Schmeeda H,Amantea M,Gehrig PA .2012 .Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol, 69 : 43-50.
Boers‑Sonder en MJ ,van Herpen CM,van der Graaf WT,Desar IM,van der Logt MG,de Beer YM .2014 .Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®). Cancer Chemother Pharmacol, 74 : 457-63.
Hunault‑Ber ger M,Leguay T,Thomas X,Legrand O .2011 .A randomizedstudyofpegylated liposomal doxorubicin versus continuous‑infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: The GRAALL‑SA1 study. Haematologica, 96 : 245-52.
Fiegl M,Mlineritsch B,Hubalek M,Bartsch R,Pluschnig U,Steger GG .2011 .Singlea‑gent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: Results of an Austrian observational trial. BMC Cancer, 11 : 373.
Wong AL,Seng KY,Ong EM,Wang LZ,Oscar H,Cordero MT .2014 .Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res Treat, 144 : 143-52.
Jurczak W,Szmit S,Sobocinski M,Machaczka M,Drozd‑Sokolowska J,Joks M .2013 .Premature cardiovascular mortality in lymphoma patients treated with (R)‑CHOP regimen - A national multicenter study. Int J Cardiol, 168 : 5212-7.
Lotrionte M,Palazzoni G,Abbate A,De Marco E,Mezzaroma E,Di Persio S .2013 .Cardiotoxicity of a non‑pegylated liposomal doxorubicin‑based regimen versus an epirubicin‑based regimen for breast cancer: The LITE (Liposomal doxorubicin‑Investigational chemotherapyT‑issue Doppler imaging Evaluation) randomized pilot study. Int J Cardiol, 167 : 1055-7.
Chastagner P,Devictor B,Geoerger B,Aerts I,Leblond P,Frappaz D .2015 .Phase I study of nonp‑egylated liposomal doxorubicin in children with recurrent/refractory high‑grade glioma. Cancer Chemother Pharmacol, 76 : 425-32.
Xu L,Wang W,Sheng YC,Zheng QS .2010 .Pharmacokinetics and its relation to toxicity of pegylated‑liposomal doxorubicin in Chinese patients with breast tumours. J Clin Pharm Ther, 35 : 593-601.
Turini M,Piovesana V,Ruffo P,Ripellino C,Cataldo N. .2015 .An assessment of chemotherapy‑induced nausea and vomiting direct costs in three EU countries. Drugs Context, 4 : 212285.
Monk BJ,Herzog TJ,Kaye SB,Krasner CN,Vermorken JB,Muggia FM .2010 .Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol, 28 : 3107-14.
Crivellari D,Gray KP,Dellapasqua S,Puglisi F,Ribi K,Price KN .2013 .Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: The CASA randomized trial. Breast, 22 : 1307.
Lee HY,Yang BM,Hong JM,Lee TJ,Kim BG,Kim JW .2013 .Cost‑utility analysis for platinum‑sensitive recurrent ovarian cancer therapy in South Korea: Results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model. Clinicoecon Outcomes Res, 5 : 297-307.
Staropoli N,Ciliberto D,Botta C,Fiorillo L,Gualtieri S,Salvino A .2013 .A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: Do we still need it. J Ovarian Res, 6 : 10.
Anders CK,Adamo B,Karginova O,Deal AM,Rawal S,Darr D .2013 .Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. PLoS One, 8 : e61359.
Bosetti R,Ferrandina G,Marneffe W,Scambia G,Vereeck L .2014 .Cost‑effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: Comparing chemotherapy with nanotherapy. Nanomedicine (Lond), 9 : 21758-6.
Vici P,Colucci G,Giotta F,Sergi D,Filippelli G,Perri P .2011 .A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first‑line treatment in advanced breast cancer. A GOIM study. J Exp Clin Cancer Res, 30 : 39.
Osoba D,Northfelt DW,Budd DW,Himmelberger D .2001 .Effect of treatment on health‑related quality of life in acquired immunodeficiency syndrome (AIDS)‑related Kaposi's sarcoma: A randomized trial of pegylated‑liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine. Cancer Invest, 19 : 573-80.
Kushnir CL,Angarita AM,Havrilesky LJ,Thompson S,Spahlinger D,Sinno AK .2015 .Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD). Gynecol Oncol, 137 : 503-7.
Lal S,Mahajan A,Chen WN,Chowbay B .2010 .Pharmacogenetics of target genes across doxorubicin disposition pathway: A review. Curr Drug Metab, 11 : 115-28.
Larbi A,Rymkiewicz P,Vasudev A,Low I,Shadan NB,Mustafah S .2013 .The immune system in the elderly: A fair fight against diseases?. Aging Health, 9 : 354-7.
Ma H,Chen M,Liu J,Li Y,Li J .2015 .Serious stomatitis and esophagitis: A peculiar mucous reaction induced by pegylated liposomal doxorubicin. An Bras Dermatol, 90 3 Suppl 1 : 209-11.
Cohn DE,Shimp WS .2015 .The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum‑resistant ovarian cancer: A lowv‑alue intervention?. Gynecol Oncol Rep, 13 : 47-8.
.2005 .Cost Effectiveness and Strategic Planning (WHO‑CHOICE). [Last cited on 2015 Oct, 17 : .
0

Citations

0

Downloads

11

Views